Selective Protection KcfmfK**: 11MtapKMKtur v\ >xwl jcxl no li «-Xu.rC mx-o) cut •Oncohgfi Uk- •rocecc Attack Here 1. AGENCY: Euro RSCG Life LM&P Chicago CREATIVE TEAM: Shirin Bridges, Amy Blevins, Audrey Daras CLIENT: Medlmmune 2. AGENCY: Wishbone/ITP CREATIVE TEAM: Annie Wu, Michael Patterson CLIENT: King Pharmaceuticals 3. AGENCY: Saatchi & Saatchi Healthcare Innovation CREATIVE TEAM: Mary Rose Rogowski, Steve Rafferty CLIENT: Marine Polymer Technologies Inc. Protect normal cells while cisplatin and radiation attack • Reduce the severity of xerostomia & nephrotoxicity’2 • Help limit treatment delays or discontinuations' Approved Indications • ETHYOL' <an>ifostrt>e; is indicated to reduce the incidence of moderate to severe xerostomia to pattens undergoing postoperative radiation treatment for head and neck cancer, where the radiation port includes a subst.mtiafportion of the parotid glands • UHYOl is indicated toreduce theamtfbt m l with repeated administration of crsplalin in patients with advanced ovarian cancer or non -small-cell lung cancer. •for the approved indications, the1 chmca! data do no: surest that the effectiveness of cisplatinbascd chemotherapy regimens or radiation therapy o altered by UHY Ol . There are at present only limited data on the effects of UHYOl on the efficacy of chemotherapy or radiotherapy in other settings. ETHYOl should not be administered to |>atients mother settings where chemotherapy can jxroduce a significant survival benefit or cure, or in patients receiving definitive radiotherapy, except in the*context of a clinical study'. Safety Information • In a radiotherapy clinical trial the most common side effects with ETHYOl were nausea/vomiting •>V\: and hypotension (15%). In a chemotherapy clinical trial, the roost common side effects with ETHYOL were nausea/vomiting t%%) and hypotension iol V . • Inherits who are hypotensiveor ck-hvd/ated should not receive FfHYOL. Patients yvho are taking antih\pertensive therapy that cannot I* stopped foe 2-t hours preceding ETHYOL administration should not receive ETHYOL at doses recommended for chemotherapy. Blood pressure should be monitored during treatment. Scrum calcium levels should be monitored in patients at nsx for hypocalcemia. • Allergic manifestations including anaphylaxis and severe cutaneous reactions have been associated rarely with ETHYOL administration. ETHYOl should be permanently discontinued for serious or severe cutaneous reactions alone or for any cutaneous reaction associated with fever. • ITHYOi fc >ontraindkafed m paiimts w ill known sensitivity to amrnothiol compounds. Please see full Prescribing Information on bad. Ethybl AMIFOSTiNE
RkJQdWJsaXNoZXIy NDMwNDAx